Search results for "PHARMACOKINETICS"

showing 10 items of 458 documents

DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?

2014

Background. Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether α-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome.Methods. This was a prospective, multinational pharmacokinetic point-prevalence study including 8 α-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f TMIC) an…

MaleInternational CooperationAntibioticsadverse eventintensive care unitlaw.invention0302 clinical medicinemeropenemModels[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesadverse events; continuous infusion; extended infusion; pharmacodynamics; pharmacokinetics; Aged; Anti-Bacterial Agents; Bacterial Infections; Blood Chemical Analysis; Female; Humans; Intensive Care Units; International Cooperation; Male; Microbial Sensitivity Tests; Middle Aged; Models Statistical; Prospective Studies; Treatment Outcome; beta-Lactams; Critical Illnessantibiotic therapyProspective Studiesamoxicillin plus clavulanic acidComputingMilieux_MISCELLANEOUSbeta lactam antibioticAPACHE0303 health sciencescritical illneadultclinical trial3. Good healthcontinuous infusion; extended infusion; adverse events; pharmacokinetics; pharmacodynamics.antiinfective agent[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitologypriority journaldisease severitybeta-Lactamstatistical model Agedprospective studyHumanMicrobiology (medical)medicine.medical_specialtydrug exposureCritical IllnessImmunologybloodstream infectionMicrobial Sensitivity Testspiperacillin plus tazobactambeta-LactamsMicrobiologybeta lactam abdominal infection03 medical and health sciencescritically ill patientIntensive careAnti-Bacterial AgentcefepimepharmacodynamicsHumansDosingAdverse effectAgedModels Statistical030306 microbiologyOdds ratiomajor clinical studymortalityantibiotic sensitivityceftriaxoneProspective Studiemulticenter studypharmacodynamics.ampicillinBlood Chemical AnalysisCeftazidimeSettore MED/41 - AnestesiologiaInterquartile rangelaw030212 general & internal medicinepharmacokineticlung infectionMicrobial Sensitivity TestarticleBacterial InfectionsMiddle AgedStatisticalcontinuous infusionIntensive care unitAnti-Bacterial Agentsextended infusionIntensive Care UnitsInfectious DiseasesTreatment Outcomeadverse events; continuous infusion; extended infusion; pharmacodynamics; pharmacokinetics; Aged; Anti-Bacterial Agents; Bacterial Infections; Blood Chemical Analysis; Female; Humans; Intensive Care Units; International Cooperation; Male; Microbial Sensitivity Tests; Middle Aged; Models Statistical; Prospective Studies; Treatment Outcome; beta-Lactams; Critical Illness; Microbiology (medical); Infectious Diseasescefazolin[SDV.IMM]Life Sciences [q-bio]/Immunologyblood samplingFemalepharmacokineticsmedicine.drugmedicine.drug_classprevalencedoripenemminimum inhibitory concentrationBacterial InfectionInternal medicinemedicinecontrolled studyblood analysibusiness.industryBlood Chemical Analysiadverse eventsSurgerypharmacodynamicdrug blood levelbusiness
researchProduct

Quantitative evaluation of ethane and n-pentane as indicators of lipid peroxidation in vivo.

1983

The use of exhalation of ethane and n-pentane in experimental animals as parameters of lipid peroxidation led to an examination of pharmacokinetics of both compounds in rats. When rats were exposed, in a closed desiccator jar chamber, to a wide range of ethane concentrations, linear elimination pharmacokinetics were observed. n-Pentane, when concentrations higher than 100 ppm were applied, displayed saturation kinetics. These were formally explained by action of two competing metabolizing pathways or enzymes. Application of preexisting models could describe exhalation of both ethane and n-pentane by untreated control rats. Stimulation of lipid peroxidation by ferrous ions or by carbon tetra…

MaleLipid PeroxidesChromatography GasHealth Toxicology and MutagenesisIronKineticsInorganic chemistryPentanesToxicologyLipid peroxidationchemistry.chemical_compoundPharmacokineticsPentanesAnimalsCarbon TetrachlorideEthaneChromatographyExhalationRats Inbred StrainsGeneral MedicineMetabolismRatsPentaneKineticschemistryBreath TestsCarbon tetrachlorideArchives of toxicology
researchProduct

Pharmacokinetics of methylmethacrylate monomer during total hip replacement in man.

1988

The concentration of methylmethacrylate monomer (MMA) in the blood stream after implantation of the components of 15 total hip prostheses using bone cement was determined in the pulmonary artery, the radial artery, and the superior vena cava after cement application, and correlated with the observed drop in blood pressure and the increase in the pulmonary arterial pressure. In all samples MMA was found. The values ranged from 0.02 micrograms/ml to 59 micrograms/ml. The mean maximum value after implantation of the stem was measured to be 7.8 micrograms/ml in the pulmonary artery, 4.6 micrograms/ml in the radial artery, and 1.75 micrograms/ml in the superior vena cava. After implantation of t…

MaleMean arterial pressureChromatography GasVena Cava SuperiorBlood PressurePulmonary ArteryPharmacokineticsSuperior vena cavamedicine.arterymedicineHumansMethylmethacrylatesOrthopedics and Sports MedicineRadial arteryAgedAged 80 and overbusiness.industryGeneral MedicineMiddle AgedBone cementBlood pressureAnesthesiaCirculatory systemPulmonary arterySurgeryFemaleHip ProsthesisNuclear medicinebusinessArchives of orthopaedic and traumatic surgery. Archiv fur orthopadische und Unfall-Chirurgie
researchProduct

Controlled transdermal iontophoresis for poly-pharmacotherapy: Simultaneous delivery of granisetron, metoclopramide and dexamethasone sodium phosphat…

2015

Iontophoresis has been used to deliver small molecules, peptides and proteins into and across the skin. In principle, it provides a controlled, non-invasive method for poly-pharmacotherapy since it is possible to formulate and to deliver multiple therapeutic agents simultaneously from the anodal and cathodal compartments. The objective of this proof-of-principle study was to investigate the simultaneous anodal iontophoretic delivery of granisetron (GST) and metoclopramide (MCL) and cathodal iontophoresis of dexamethasone sodium phosphate (DEX-P). In addition to validating the hypothesis, these are medications that are routinely used in combination to treat chemotherapy-induced emesis. Two p…

MaleMetoclopramideSwinePharmaceutical Science02 engineering and technologyPharmacologyGranisetronAdministration Cutaneous030226 pharmacology & pharmacyDexamethasoneGranisetron03 medical and health sciences0302 clinical medicineDexamethasone Sodium PhosphatePharmacokineticsIn vivomedicineAnimalsRats WistarDexamethasoneActive metaboliteTransdermalSkinIontophoresisChemistryHydrolysisIontophoresis021001 nanoscience & nanotechnologyRatsPolypharmacy0210 nano-technologymedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients

2015

Background: Infliximab, an anti-tumour necrosis factor approved for treatment of Crohn's disease and ulcerative colitis, is administered at predefined interdose-intervals. On insufficient response or loss of response, treatment can be intensified. The lack or loss of response is likely related to complex pharmacokinetics of infliximab. Aims: To explore optimal dosing strategies of infliximab in treatment-naïve patients with ulcerative colitis through predictive Monte Carlo simulations based on a validated population PK model. Methods: A population of 2,000 treatment-naïve patients was generated by Montecarlo simulation. Six dosing strategies for maintenance therapy were simulated on this po…

MaleModels StatisticalDose-Response Relationship DrugUlcerativeColitisInfliximabTreatment OutcomeGastrointestinal AgentsHumanslcsh:Diseases of the digestive system. GastroenterologyColitis UlcerativeComputer SimulationFemalePharmacokineticslcsh:RC799-869Monte Carlo Method
researchProduct

Pharmacokinetic Interaction between Nevirapine and Nortriptyline in Rats: Inhibition of Nevirapine Metabolism by Nortriptyline

2014

ABSTRACTOne of the most frequent comorbidities of HIV infection is depression, with a lifetime prevalence of 22 to 45%. Therefore, it was decided to study a potential pharmacokinetic interaction between the nonnucleoside reverse transcriptase inhibitor nevirapine (NVP) and the tricyclic antidepressant nortriptyline (NT). NVP and NT were administered to rats either orally, intraduodenally, or intravenously, and the changes in plasma levels and pharmacokinetic parameters were analyzed. Experiments with rat and human hepatic microsomes were carried out to evaluate the inhibitory effects of NT on NVP metabolism. NVP plasma concentrations were significantly higher when this drug was coadminister…

MaleNevirapineAnti-HIV AgentsAdministration OralNortriptylineAntidepressive Agents TricyclicPharmacologyPharmacokineticsimmune system diseasesIn vivomedicineAnimalsHumansPharmacology (medical)NevirapineRats WistarBiotransformationPharmacologyDose-Response Relationship DrugReverse-transcriptase inhibitorbusiness.industryvirus diseasesRatsDose–response relationshipInfectious DiseasesArea Under CurveInjections IntravenousMicrosomes LiverMicrosomeReverse Transcriptase InhibitorsNortriptylinebusinessDrug AntagonismDrug metabolismmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-…

2009

Abstract Background This phase I dose-escalation study was designed to determine the maximum tolerated dose (MTD) and recommended dose of cetuximab administered on an every-second-week schedule to patients with metastatic colorectal cancer, on the basis of safety, pharmacokinetic and pharmacodynamic evaluation. Patients and methods The study comprised two parts: a 6-week cetuximab monotherapy dose-escalation phase and a subsequent combination therapy phase, during which patients received cetuximab, at the same dose/schedule as in the monotherapy phase, followed by irinotecan plus infusional 5-fluorouracil/folinic acid (FOLFIRI). Patients in the control group received cetuximab as a 400 mg/m…

MaleOncologymedicine.medical_specialtyMaximum Tolerated DoseCombination therapyColorectal cancerLeucovorinCetuximabAntibodies Monoclonal HumanizedIrinotecanImmunoenzyme TechniquesFolinic acidPharmacokineticsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTissue DistributionneoplasmsAgedDose-Response Relationship DrugCetuximabbusiness.industryAntibodies MonoclonalHematologyMiddle Agedmedicine.diseasedigestive system diseasesSurgeryErbB ReceptorsSurvival RateIrinotecanTreatment OutcomeOncologyPharmacodynamicsFOLFIRICamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

A Model‐Based Workflow to Benchmark the Clinical Cholestasis Risk of Drugs

2021

We present a generic workflow combining physiology-based computational modeling and in vitro data to assess the clinical cholestatic risk of different drugs systematically. Changes in expression levels of genes involved in the enterohepatic circulation of bile acids were obtained from an in vitro assay mimicking 14 days of repeated drug administration for 10 marketed drugs. These changes in gene expression over time were contextualized in a physiology-based bile acid model of glycochenodeoxycholic acid. The simulated drug-induced response in bile acid concentrations was then scaled with the applied drug doses to calculate the cholestatic potential for each compound. A ranking of the cholest…

MalePHARMACOKINETICSAZATHIOPRINEAzathioprineBioinformatics030226 pharmacology & pharmacyWorkflowchemistry.chemical_compound0302 clinical medicinePARACETAMOLPharmacology (medical)Enterohepatic circulationmedia_common0303 health sciencesCholestasisBile acidMiddle Aged3. Good healthBenchmarkingLiverPharmaceutical PreparationsSINGLEDrug developmentFemaleVALPROATEmedicine.drugAdultDrugDrug-Related Side Effects and Adverse ReactionsDICLOFENAC SODIUMmedicine.drug_classmedia_common.quotation_subjectModels BiologicalYoung Adult03 medical and health sciencesCholestasisPharmacokineticsSpheroids CellularmedicineGlycochenodeoxycholic acidAnimalsHumansddc:610030304 developmental biologyPharmacologybusiness.industrymedicine.diseasechemistryACETAMINOPHENbusinessClinical Pharmacology & Therapeutics
researchProduct

Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's dise…

2018

[EN] Effective treatment of Parkinson's disease (PD) involves administration of therapeutic agents with complementary mechanisms of action in order to replenish, sustain or substitute endogenous dopamine. The objective of this study was to investigate anodal co-iontophoresis of pramipexole (PRAM; dopamine agonist) and rasagiline (RAS; MAO-B inhibitor) in vitro and in vivo. Passive permeation of PRAM and RAS (20 mM each) across porcine skin after 6 h was 15.7 +/- 1.9 and 16.0 +/- 2.9 mu g/cm(2), respectively. Co-iontophoresis at 0.15, 0.3 and 0.5 mA/cm(2) resulted in statistically significant increases in delivery of PRAM and RAS; at 0.5 mA/cm(2), cumulative permeation of PRAM and RAS was 61…

MaleParkinson's diseaseSwineChemistry PharmaceuticalSkin AbsorptionPharmaceutical SciencePharmacologyAdministration Cutaneous030226 pharmacology & pharmacyDopamine agonistPermeability03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePramipexolePharmacokineticsIn vivomedicineAnimalsHumansBenzothiazolesMAO-B inhibitorRats WistarTransdermalSkinRasagilinePramipexoleIontophoresisDopamine agonistPatient complianceParkinson DiseaseGeneral MedicineIontophoresismedicine.diseaseRatschemistryIndansPolypharmacyElectroosmosisTransdermal030217 neurology & neurosurgeryBiotechnologymedicine.drugEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Magnetic resonance pharmacokinetic imaging clusterization of hepatocellular carcinomas as a means to grade tumor aggressiveness.

2012

Hepatocellular carcinoma (HCC) management takes into account clinical and radiological findings, such as tumor stage, hepatic functional status and clinical symptoms. It is necessary to evaluate the number, size and location of the lesions. However, lesion aggressiveness is not considered in this therapeutic workflow, although the biology and the growth rate of the lesions have an important impact on survival. The aim of this work was to establish if the quantitative pharmacokinetic assessment of dynamic contrast-enhanced magnetic resonance images of HCC can separate lesions with different microvascular properties and biological evolution. Forty five patients with HCC and dynamic contrast-e…

MalePathologymedicine.medical_specialtyCarcinoma HepatocellularPharmacokinetic modelingContrast MediaKaplan-Meier EstimateLesionCapillary PermeabilityPharmacokineticsTumor stagemedicineBiomarkers TumorCluster AnalysisHumansAgedHepatologymedicine.diagnostic_testbusiness.industryLiver NeoplasmsGastroenterologyMagnetic resonance imagingBiological evolutionMiddle Agedmedicine.diseaseImage EnhancementMagnetic Resonance ImagingHepatocellular carcinomaDisease ProgressionFunctional statusFemalemedicine.symptomNeoplasm GradingbusinessExpert review of gastroenterologyhepatology
researchProduct